Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient enrollment and reinfusion in an investigator-initiated trial (ITT) for its CNK-UT cell therapy, targeting advanced solid tumors at Shulan Hangzhou Hospital.
CNK-UT Cell Therapy: A Universal Cell Technology for Tumor Treatment
CNK-UT is a groundbreaking universal cell technology that integrates the CNK-T and U-T platform technologies of Yizun Bio. This therapy involves collecting T cells from healthy donors, modifying them through genome editing, and endowing NK cells with the recognition function and the activation and attack capabilities of T cells. This enables specific recognition and treatment of tumors. The same CNK-UT cells can target and kill multiple tumor cells, holding the potential to provide a broad-spectrum indication for pan-cancer cell therapy.
Yizun Bio’s Partnerships and Facilities
Founded in 2018, Yizun Bio established a partnership with Livzon Pharmaceutical Group Inc. (HKG: 1513) in June 2019, securing an investment of “tens of millions” of RMB. The company prides itself on its CNK-T, VAC-T, and UT technology platforms, along with 3000 square meters of GMP compliant facilities. In December 2022, Yizun Bio further expanded its reach by striking a partnership with US firm Azenta Life Sciences (NASDAQ: AZTA) to bolster the development of industrial cell pharmaceutical enterprises.-Fineline Info & Tech
